<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mecha J</submitter><funding>NICHD NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>FIC NIH HHS</funding><funding>NIH HHS</funding><pagination>250-256</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10922277</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>43(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The effect of maternal HIV on infant Mycobacterium tuberculosis (Mtb) infection risk is not well-characterized.&lt;h4>Methods&lt;/h4>Pregnant women with/without HIV and their infants were enrolled in a longitudinal cohort in Kenya. Mothers had interferon gamma-release assays (QFT-Plus) and tuberculin skin tests (TST) at enrollment in pregnancy; children underwent TST at 12 and 24 months of age. We estimated the incidence and correlates of infant TST-positivity using Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Among 322 infants, 170 (53%) were HIV-exposed and 152 (47%) were HIV-unexposed. Median enrollment age was 6.6 weeks [interquartile range (IQR): 6.1-10.0]; most received Bacillus Calmette-Guerin (320, 99%). Thirty-nine (12%) mothers were TST-positive; 102 (32%) were QFT-Plus-positive. Among HIV-exposed infants, 154 (95%) received antiretrovirals for HIV prevention and 141 (83%) of their mothers ever received isoniazid preventive therapy (IPT). Cumulative 24-month infant Mtb infection incidence was 3.6/100 person-years (PY) [95% confidence interval (CI): 2.4-5.5/100 PY]; 5.4/100 PY in HIV-exposed infants (10%, 17/170) versus 1.7/100 PY in HIV-unexposed infants (3.3%, 5/152) [hazard ratio (HR): 3.1 (95% CI: 1.2-8.5)]. More TST conversions occurred in the first versus second year of life [5.8 vs. 2.0/100 PY; HR: 2.9 (95% CI: 1.0-10.1)]. Infant TST-positivity was associated with maternal TST-positivity [HR: 2.9 (95% CI: 1.1-7.4)], but not QFT-Plus-positivity. Among HIV-exposed children, Mtb infection incidence was similar regardless of maternal IPT.&lt;h4>Conclusions&lt;/h4>Mtb infection incidence (by TST) by 24 months of age was ~3-fold higher among HIV-exposed children, despite high maternal IPT uptake. Overall, more TST conversions occurred in the first 12 months compared to 12-24 months of age, similar in both HIV-exposed and HIV-unexposed children.</pubmed_abstract><journal>The Pediatric infectious disease journal</journal><pubmed_title>Maternal HIV Status and Risk of Infant Mycobacterium tuberculosis Infection as Measured by Tuberculin Skin Test.</pubmed_title><pmcid>PMC10922277</pmcid><funding_grant_id>P30 AI168034</funding_grant_id><funding_grant_id>K23 AI120793</funding_grant_id><funding_grant_id>R01 AI142647</funding_grant_id><funding_grant_id>R21 HD098746</funding_grant_id><funding_grant_id>UL1TR000423</funding_grant_id><funding_grant_id>D43 TW011817</funding_grant_id><funding_grant_id>UL1 TR000423</funding_grant_id><pubmed_authors>Matemo D</pubmed_authors><pubmed_authors>Escudero JN</pubmed_authors><pubmed_authors>LaCourse SM</pubmed_authors><pubmed_authors>Mecha J</pubmed_authors><pubmed_authors>Kinuthia J</pubmed_authors><pubmed_authors>John-Stewart G</pubmed_authors><pubmed_authors>Richardson BA</pubmed_authors><pubmed_authors>Maleche-Obimbo E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Maternal HIV Status and Risk of Infant Mycobacterium tuberculosis Infection as Measured by Tuberculin Skin Test.</name><description>&lt;h4>Background&lt;/h4>The effect of maternal HIV on infant Mycobacterium tuberculosis (Mtb) infection risk is not well-characterized.&lt;h4>Methods&lt;/h4>Pregnant women with/without HIV and their infants were enrolled in a longitudinal cohort in Kenya. Mothers had interferon gamma-release assays (QFT-Plus) and tuberculin skin tests (TST) at enrollment in pregnancy; children underwent TST at 12 and 24 months of age. We estimated the incidence and correlates of infant TST-positivity using Cox proportional hazards regression.&lt;h4>Results&lt;/h4>Among 322 infants, 170 (53%) were HIV-exposed and 152 (47%) were HIV-unexposed. Median enrollment age was 6.6 weeks [interquartile range (IQR): 6.1-10.0]; most received Bacillus Calmette-Guerin (320, 99%). Thirty-nine (12%) mothers were TST-positive; 102 (32%) were QFT-Plus-positive. Among HIV-exposed infants, 154 (95%) received antiretrovirals for HIV prevention and 141 (83%) of their mothers ever received isoniazid preventive therapy (IPT). Cumulative 24-month infant Mtb infection incidence was 3.6/100 person-years (PY) [95% confidence interval (CI): 2.4-5.5/100 PY]; 5.4/100 PY in HIV-exposed infants (10%, 17/170) versus 1.7/100 PY in HIV-unexposed infants (3.3%, 5/152) [hazard ratio (HR): 3.1 (95% CI: 1.2-8.5)]. More TST conversions occurred in the first versus second year of life [5.8 vs. 2.0/100 PY; HR: 2.9 (95% CI: 1.0-10.1)]. Infant TST-positivity was associated with maternal TST-positivity [HR: 2.9 (95% CI: 1.1-7.4)], but not QFT-Plus-positivity. Among HIV-exposed children, Mtb infection incidence was similar regardless of maternal IPT.&lt;h4>Conclusions&lt;/h4>Mtb infection incidence (by TST) by 24 months of age was ~3-fold higher among HIV-exposed children, despite high maternal IPT uptake. Overall, more TST conversions occurred in the first 12 months compared to 12-24 months of age, similar in both HIV-exposed and HIV-unexposed children.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-18T21:19:01.484Z</modification><creation>2025-04-07T09:15:24.065Z</creation></dates><accession>S-EPMC10922277</accession><cross_references><pubmed>37991383</pubmed><doi>10.1097/inf.0000000000004190</doi><doi>10.1097/INF.0000000000004190</doi></cross_references></HashMap>